author_facet Zaric, Radica Zivkovic
Milovanovic, Jasmina
Rosic, Nikola
Milovanovic, Dragan
Zecevic, Dejana Ruzic
Folic, Marko
Jankovic, Slobodan
Zaric, Radica Zivkovic
Milovanovic, Jasmina
Rosic, Nikola
Milovanovic, Dragan
Zecevic, Dejana Ruzic
Folic, Marko
Jankovic, Slobodan
author Zaric, Radica Zivkovic
Milovanovic, Jasmina
Rosic, Nikola
Milovanovic, Dragan
Zecevic, Dejana Ruzic
Folic, Marko
Jankovic, Slobodan
spellingShingle Zaric, Radica Zivkovic
Milovanovic, Jasmina
Rosic, Nikola
Milovanovic, Dragan
Zecevic, Dejana Ruzic
Folic, Marko
Jankovic, Slobodan
Open Medicine
Pharmacokinetics of vancomycin in patients with different renal function levels
General Medicine
author_sort zaric, radica zivkovic
spelling Zaric, Radica Zivkovic Milovanovic, Jasmina Rosic, Nikola Milovanovic, Dragan Zecevic, Dejana Ruzic Folic, Marko Jankovic, Slobodan 2391-5463 Walter de Gruyter GmbH General Medicine http://dx.doi.org/10.1515/med-2018-0068 <jats:title>Abstract</jats:title> <jats:p>There are many determinants of vancomycin clearance, but these have not been analyzed separately in populations with different levels of renal function, which could be why some important factors have been missed. The aim of our study was to compare the pharmacokinetic parameters and factors that may affect vancomycin pharmacokinetics in groups of patients with normal renal function and in those with chronic kidney failure. The study used a population pharmacokinetic modeling approach, based on plasma vancomycin concentrations and other data from 78 patients with chronic kidney failure and 32 patients with normal renal function. The model was developed using NONMEM software and validated by bootstrapping. The final model for patients with impaired kidney function was described by the following equation: CL (L/h) = 0.284 + 0.000596 x DD + 0.00194 x AST, and that for the patients with normal kidney function by: CL (L/h) = 0.0727 + 0.205 x FIB. If our results are confirmed by new studies on two similar populations, these factors could be considered when dosing vancomycin in patients with chronically damaged kidneys, as well as in patients with normal kidneys who frequently require high doses of vancomycin.</jats:p> Pharmacokinetics of vancomycin in patients with different renal function levels Open Medicine
doi_str_mv 10.1515/med-2018-0068
facet_avail Online
Free
format ElectronicArticle
fullrecord blob:ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9tZWQtMjAxOC0wMDY4
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9tZWQtMjAxOC0wMDY4
institution DE-15
DE-Pl11
DE-Rs1
DE-14
DE-105
DE-Ch1
DE-L229
DE-D275
DE-Bn3
DE-Brt1
DE-Zwi2
DE-D161
DE-Zi4
DE-Gla1
imprint Walter de Gruyter GmbH, 2018
imprint_str_mv Walter de Gruyter GmbH, 2018
issn 2391-5463
issn_str_mv 2391-5463
language English
mega_collection Walter de Gruyter GmbH (CrossRef)
match_str zaric2018pharmacokineticsofvancomycininpatientswithdifferentrenalfunctionlevels
publishDateSort 2018
publisher Walter de Gruyter GmbH
recordtype ai
record_format ai
series Open Medicine
source_id 49
title Pharmacokinetics of vancomycin in patients with different renal function levels
title_unstemmed Pharmacokinetics of vancomycin in patients with different renal function levels
title_full Pharmacokinetics of vancomycin in patients with different renal function levels
title_fullStr Pharmacokinetics of vancomycin in patients with different renal function levels
title_full_unstemmed Pharmacokinetics of vancomycin in patients with different renal function levels
title_short Pharmacokinetics of vancomycin in patients with different renal function levels
title_sort pharmacokinetics of vancomycin in patients with different renal function levels
topic General Medicine
url http://dx.doi.org/10.1515/med-2018-0068
publishDate 2018
physical 512-519
description <jats:title>Abstract</jats:title> <jats:p>There are many determinants of vancomycin clearance, but these have not been analyzed separately in populations with different levels of renal function, which could be why some important factors have been missed. The aim of our study was to compare the pharmacokinetic parameters and factors that may affect vancomycin pharmacokinetics in groups of patients with normal renal function and in those with chronic kidney failure. The study used a population pharmacokinetic modeling approach, based on plasma vancomycin concentrations and other data from 78 patients with chronic kidney failure and 32 patients with normal renal function. The model was developed using NONMEM software and validated by bootstrapping. The final model for patients with impaired kidney function was described by the following equation: CL (L/h) = 0.284 + 0.000596 x DD + 0.00194 x AST, and that for the patients with normal kidney function by: CL (L/h) = 0.0727 + 0.205 x FIB. If our results are confirmed by new studies on two similar populations, these factors could be considered when dosing vancomycin in patients with chronically damaged kidneys, as well as in patients with normal kidneys who frequently require high doses of vancomycin.</jats:p>
container_issue 1
container_start_page 512
container_title Open Medicine
container_volume 13
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
_version_ 1792342995269320709
geogr_code not assigned
last_indexed 2024-03-01T16:44:38.895Z
geogr_code_person not assigned
openURL url_ver=Z39.88-2004&ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fvufind.svn.sourceforge.net%3Agenerator&rft.title=Pharmacokinetics+of+vancomycin+in+patients+with+different+renal+function+levels&rft.date=2018-10-22&genre=article&issn=2391-5463&volume=13&issue=1&spage=512&epage=519&pages=512-519&jtitle=Open+Medicine&atitle=Pharmacokinetics+of+vancomycin+in+patients+with+different+renal+function+levels&aulast=Jankovic&aufirst=Slobodan&rft_id=info%3Adoi%2F10.1515%2Fmed-2018-0068&rft.language%5B0%5D=eng
SOLR
_version_ 1792342995269320709
author Zaric, Radica Zivkovic, Milovanovic, Jasmina, Rosic, Nikola, Milovanovic, Dragan, Zecevic, Dejana Ruzic, Folic, Marko, Jankovic, Slobodan
author_facet Zaric, Radica Zivkovic, Milovanovic, Jasmina, Rosic, Nikola, Milovanovic, Dragan, Zecevic, Dejana Ruzic, Folic, Marko, Jankovic, Slobodan, Zaric, Radica Zivkovic, Milovanovic, Jasmina, Rosic, Nikola, Milovanovic, Dragan, Zecevic, Dejana Ruzic, Folic, Marko, Jankovic, Slobodan
author_sort zaric, radica zivkovic
container_issue 1
container_start_page 512
container_title Open Medicine
container_volume 13
description <jats:title>Abstract</jats:title> <jats:p>There are many determinants of vancomycin clearance, but these have not been analyzed separately in populations with different levels of renal function, which could be why some important factors have been missed. The aim of our study was to compare the pharmacokinetic parameters and factors that may affect vancomycin pharmacokinetics in groups of patients with normal renal function and in those with chronic kidney failure. The study used a population pharmacokinetic modeling approach, based on plasma vancomycin concentrations and other data from 78 patients with chronic kidney failure and 32 patients with normal renal function. The model was developed using NONMEM software and validated by bootstrapping. The final model for patients with impaired kidney function was described by the following equation: CL (L/h) = 0.284 + 0.000596 x DD + 0.00194 x AST, and that for the patients with normal kidney function by: CL (L/h) = 0.0727 + 0.205 x FIB. If our results are confirmed by new studies on two similar populations, these factors could be considered when dosing vancomycin in patients with chronically damaged kidneys, as well as in patients with normal kidneys who frequently require high doses of vancomycin.</jats:p>
doi_str_mv 10.1515/med-2018-0068
facet_avail Online, Free
format ElectronicArticle
format_de105 Article, E-Article
format_de14 Article, E-Article
format_de15 Article, E-Article
format_de520 Article, E-Article
format_de540 Article, E-Article
format_dech1 Article, E-Article
format_ded117 Article, E-Article
format_degla1 E-Article
format_del152 Buch
format_del189 Article, E-Article
format_dezi4 Article
format_dezwi2 Article, E-Article
format_finc Article, E-Article
format_nrw Article, E-Article
geogr_code not assigned
geogr_code_person not assigned
id ai-49-aHR0cDovL2R4LmRvaS5vcmcvMTAuMTUxNS9tZWQtMjAxOC0wMDY4
imprint Walter de Gruyter GmbH, 2018
imprint_str_mv Walter de Gruyter GmbH, 2018
institution DE-15, DE-Pl11, DE-Rs1, DE-14, DE-105, DE-Ch1, DE-L229, DE-D275, DE-Bn3, DE-Brt1, DE-Zwi2, DE-D161, DE-Zi4, DE-Gla1
issn 2391-5463
issn_str_mv 2391-5463
language English
last_indexed 2024-03-01T16:44:38.895Z
match_str zaric2018pharmacokineticsofvancomycininpatientswithdifferentrenalfunctionlevels
mega_collection Walter de Gruyter GmbH (CrossRef)
physical 512-519
publishDate 2018
publishDateSort 2018
publisher Walter de Gruyter GmbH
record_format ai
recordtype ai
series Open Medicine
source_id 49
spelling Zaric, Radica Zivkovic Milovanovic, Jasmina Rosic, Nikola Milovanovic, Dragan Zecevic, Dejana Ruzic Folic, Marko Jankovic, Slobodan 2391-5463 Walter de Gruyter GmbH General Medicine http://dx.doi.org/10.1515/med-2018-0068 <jats:title>Abstract</jats:title> <jats:p>There are many determinants of vancomycin clearance, but these have not been analyzed separately in populations with different levels of renal function, which could be why some important factors have been missed. The aim of our study was to compare the pharmacokinetic parameters and factors that may affect vancomycin pharmacokinetics in groups of patients with normal renal function and in those with chronic kidney failure. The study used a population pharmacokinetic modeling approach, based on plasma vancomycin concentrations and other data from 78 patients with chronic kidney failure and 32 patients with normal renal function. The model was developed using NONMEM software and validated by bootstrapping. The final model for patients with impaired kidney function was described by the following equation: CL (L/h) = 0.284 + 0.000596 x DD + 0.00194 x AST, and that for the patients with normal kidney function by: CL (L/h) = 0.0727 + 0.205 x FIB. If our results are confirmed by new studies on two similar populations, these factors could be considered when dosing vancomycin in patients with chronically damaged kidneys, as well as in patients with normal kidneys who frequently require high doses of vancomycin.</jats:p> Pharmacokinetics of vancomycin in patients with different renal function levels Open Medicine
spellingShingle Zaric, Radica Zivkovic, Milovanovic, Jasmina, Rosic, Nikola, Milovanovic, Dragan, Zecevic, Dejana Ruzic, Folic, Marko, Jankovic, Slobodan, Open Medicine, Pharmacokinetics of vancomycin in patients with different renal function levels, General Medicine
title Pharmacokinetics of vancomycin in patients with different renal function levels
title_full Pharmacokinetics of vancomycin in patients with different renal function levels
title_fullStr Pharmacokinetics of vancomycin in patients with different renal function levels
title_full_unstemmed Pharmacokinetics of vancomycin in patients with different renal function levels
title_short Pharmacokinetics of vancomycin in patients with different renal function levels
title_sort pharmacokinetics of vancomycin in patients with different renal function levels
title_unstemmed Pharmacokinetics of vancomycin in patients with different renal function levels
topic General Medicine
url http://dx.doi.org/10.1515/med-2018-0068